Sifalimumab Shows Promise in Study of Moderate to Severe SLE

Newly Published Results

The efficacy and safety of sifalimumab were assessed in a phase IIb, randomized, double-blind, placebo-controlled study (NCT01283139) of adults with moderate to severe active systemic lupus erythematosus (SLE). Results were published in Annals of the Rheumatic Diseases

431 patients received monthly intravenous sifalimumab in doses of 200 mg, 600 mg or 1200 mg or placebo in addition to standard-of-care medications.  Compared with placebo, a greater percentage of patients who received sifalimumab at all dosages met the primary end point which was improvement as measured by a standard evaluation tool. Adverse side effects were considered similar among patients treated with sifalimumab compared with placebo; however hHerpes zoster infections were more frequent with sifalimumab. 

Investigators concluded that sifalimumab is a promising treatment for adults with SLE.